298. Hereditary pancreatitis
93 clinical trials,   168 drugs   (DrugBank: 51 drugs),   48 drug target genes,   134 drug target pathways

Searched query = "Hereditary pancreatitis", "Chronic pancreatitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03481803
(ClinicalTrials.gov)
January 27, 20176/3/2018A Phase IIa Study With Escalating Dose of MS1819-SDA Multicentre Open-label Phase IIa Study With Escalating Dose of MS1819- SD, to Investigate the Efficacy and Safety of a Yarrowia Lipolytica Lipase Preparation for the Compensation of Exocrine Pancreatic Insufficiency Caused by Chronic Pancreatitis and/or Distal PancreatectomyChronic Pancreatitis;Distal PancreatectomyDrug: MS1819-SDAzurRx SASNULLCompleted18 YearsN/AAll11Phase 2Australia;France;New Zealand
2EUCTR2010-018900-10-FR
(EUCTR)
11/05/201019/03/2010Safety and preliminary clinical activity of Yarrowia lipolytica lipase (MS1819) in patients with malabsorption syndrome due to exocrine pancreatic insufficiency resulting from chronic pancreatitisSafety and preliminary clinical activity of Yarrowia lipolytica lipase (MS1819) in patients with malabsorption syndrome due to exocrine pancreatic insufficiency resulting from chronic pancreatitis Exocrine pancreatic insufficiency resulting from chronic pancreatitis
MedDRA version: 12.1;Level: LLT;Classification code 10033628;Term: Pancreatic insufficiency
Product Name: MS1819
Product Code: MS1819
INN or Proposed INN: Yarrowia lipolytica lipase
Laboratoires Mayoly SpindlerNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
12France